MorningStar Expands SmartVascular Dx Heart Test Access to California Patients

MorningStar’s Test Reached California

Image Credits: AInvest

Announcement

MorningStar Laboratories, LLC (MSL), a global developer of precision diagnostic tests that analyze clinical needs, is proud to announce the availability of the Smartvascular Dx test (PULS Cardiac test) to patients in California. The expansion of this new test in California was successful through a partnership with valuable health plans, also Health Net and L. A Care health plan. Further, MSL ensures coverage for various carriers such as Cigna, Aetna, Humana, and UHC under contracts with Contigo Health, Medical Cost Containment Professional, TRPN Direct Pay, and Unity Preferred Nationwide PPO Network.

SmartVascular Dx Test

The SmartVascular Dx test is different from other heart disease tests. This test is an innovative test that protects the endothelium and arteries. The damage can turn into cardiac lesions. The SmartVascular Dx test detects risk and disease stages that lead to progression of the disease and doubles the value of this test. SmartVascular Dx test can predict cardiac events that might be visible in the next five years. It enables insights for management and preventive care.

Additionally, MorningStar Laboratories has invited interested healthcare providers to engage in setting up new accounts and approach this vital diagnostic tool.

How does the Expansion of Testing Contribute to the Healthcare Market?

The healthcare market approach for technological advancements and new developments to enhance the competitive landscape has been a never-ending race towards achieving significant milestones. Access to the SmartVascular Dx test in California has led to the expansion of the test and the company’s recognition. The test is aligned with several medical conditions like cancer, autoimmune diseases, metabolic abnormalities, COVID-19, diabetes, and infections.

The reach of this test has multiple effective solutions to these medical conditions. The pandemic has flowed since 2019 and highlighted the need for certain tests and treatments. The uncertainty has elevated the value of an introduction to innovative testing. Those who learn to explore learns to expand and understand certain needs to meet patients' health problems. The availability of the test is an advantage to the patients and an opportunity for healthcare professionals to serve in the best way possible.

Views and Statements

MD, Medical Director, Paul Krishman, said, “With the integration of the SmartVascular Dx test into practices, California-based physicians can stand a chance to play a major role in minimizing vascular risk in patients. The company believes that one who can recognize early defects has the potential to improve patients’ recovery and save lives.”